PLK1 and acute myeloid leukemia: The results showed that the high-risk group showed a lower sensitivity to BI2536 (PLK1 inhibitor) and SB-505124 (TGFβR inhibitor), whereas they were sensitive to several other drugs such as AZD2014 (mTOR inhibitor), pictilisib (PI3Kα/δ inhibitor), MK-2206 (Akt inhibitor), dactolisib (dual pan-class I PI3K and mTOR kinase inhibitor), afatinib (EGFR inhibitor), rapamycin (FRAP/mTOR inhibitor), and taselisib (PI3K inhibitor targets PIK3CA mutations), even though none of these is currently used in the treatment of AML (Figure 9).